Merck's Multi-Billion Dollar Partnership with Daiichi Sankyo for Cancer Therapies
TL;DR Summary
Merck has entered into a partnership with Daiichi Sankyo, committing $4 billion upfront, to co-develop and co-commercialize three antibody-drug conjugates (ADCs) from Daiichi's DXd platform. The ADCs target HER3, B7-H3, and CDH6, with the most advanced program set for a BLA filing by the end of March 2024. This partnership adds momentum to the growing ADC space, which has seen blockbuster revenue, data readouts, and increased M&A activity.
Topics:business#antibody-drug-conjugates#daiichi-sankyo#dollar4-billion-upfront#merck#partnership#pharmaceuticals
- Merck partners with Daiichi Sankyo in ADC deal with $4B upfront – Endpoints News Endpoints News
- Merck signs $5.5 bln deal with Daiichi for cancer therapy development Reuters
- Merck, Daiichi strike cancer drug pact worth up to $22 billion STAT
- Merck pays $4B for Daiichi ADCs in bet on post-Keytruda future FierceBiotech
- Merck Bets Big on ADCs with $4B+ Daiichi Sankyo Deal Inside Precision Medicine
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
0 min
vs 1 min read
Condensed
47%
129 → 68 words
Want the full story? Read the original article
Read on Endpoints News